Literature DB >> 17899288

Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum.

Sheelu Varghese1, Monika Burness, Hui Xu, Tatiana Beresnev, James Pingpank, H Richard Alexander.   

Abstract

BACKGROUND: Generally, colorectal and high-grade appendiceal cancers are treated similarly; treatment approach is primarily based on tumor histology and stage of disease. Patients with adenocarcinoma of the lower gastrointestinal tract frequently experience diffuse metastases isolated to liver or peritoneum and have a poor survival. Identification of novel molecular pathways in metastases from these patients may identify novel targets and prognostic factors.
METHODS: Microarray analyses of 20 metastatic tumors from patients with colorectal adenocarcinoma isolated to liver or peritoneum and eight high-grade appendiceal adenocarcinoma metastatic to peritoneum were performed using oligonucleotide microarray.
RESULTS: In an unsupervised hierarchical cluster analysis of 2-fold upregulated or downregulated genes, there was a clear site-specific segregation of liver versus peritoneal metastases. Genes primarily involved in metastasis, angiogenesis, cell cycle regulation, cell proliferation, and cell adhesion were distinctly altered between these two metastatic sites. Among the metastasis genes, the average expression levels of LI-cadherin, ALCAM, CD2, and CD14 were significantly higher in both metastatic sites. TIMP1 was overexpressed in both sites where as TIMP-2, IGF-1, and HIF-1alpha were upregulated only in peritoneal metastases demonstrating the potential benefit of metastasis site-specific treatments. Subsets of genes significantly associated with poor survival were defined, a RET proto-oncogene interacting gene, GOLGA5, was highly predictive for survival in patients with colorectal adenocarcinoma.
CONCLUSIONS: These results demonstrate that liver and peritoneal metastases of lower GI adenocarcinoma have distinct gene expression patterns; these distinctions may help in the development of therapies based on site of metastases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17899288     DOI: 10.1245/s10434-007-9557-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  21 in total

1.  Expression of KAP1 in epithelial ovarian cancer and its correlation with drug-resistance.

Authors:  Mingqiu Hu; Xin Fu; Yanfen Cui; Shilei Xu; Yue Xu; Qiuping Dong; Lu Sun
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 2.  Peritoneal damage: the inflammatory response and clinical implications of the neuro-immuno-humoral axis.

Authors:  Tarik Sammour; Arman Kahokehr; Mattias Soop; Andrew G Hill
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

3.  A comparison of colorectal cancer in Nigerian and North American patients: is the cancer biology different?

Authors:  Saurabh Saluja; Olusegun I Alatise; Adisa Adewale; Justine Misholy; Joanne Chou; Mithat Gonen; Martin Weiser; T Peter Kingham
Journal:  Surgery       Date:  2014-06-19       Impact factor: 3.982

Review 4.  Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers.

Authors:  E M V de Cuba; R Kwakman; M van Egmond; L J W Bosch; H J Bonjer; G A Meijer; E A te Velde
Journal:  Virchows Arch       Date:  2012-07-24       Impact factor: 4.064

5.  Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.

Authors:  Sheelu Varghese; Zhaorong Chen; David L Bartlett; James F Pingpank; Steven K Libutti; Seth M Steinberg; John Wunderlich; H Richard Alexander
Journal:  Cancer       Date:  2010-09-13       Impact factor: 6.860

Review 6.  Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review.

Authors:  Christin Lund-Andersen; Annette Torgunrud; Karianne Giller Fleten; Kjersti Flatmark
Journal:  J Gastrointest Oncol       Date:  2021-04

7.  Proteome analysis of human pancreatic cancer cell lines with highly liver metastatic potential by antibody microarray.

Authors:  Weidong Shi; Zhiqiang Meng; Zhen Chen; Jianmin Luo; Luming Liu
Journal:  Mol Cell Biochem       Date:  2010-10-20       Impact factor: 3.396

8.  CTHRC1 is associated with peritoneal carcinomatosis in colorectal cancer: a new predictor for prognosis.

Authors:  Fei Tan; Feng Liu; Hao Liu; Yanfeng Hu; Dongning Liu; Guoxin Li
Journal:  Med Oncol       Date:  2013-01-29       Impact factor: 3.064

Review 9.  Peritoneal Metastases in Colorectal Cancer: Biology and Barriers.

Authors:  Lai Xue; Neil H Hyman; Kiran K Turaga; Oliver S Eng
Journal:  J Gastrointest Surg       Date:  2019-11-19       Impact factor: 3.452

10.  Clinical applications of gene expression in colorectal cancer.

Authors:  Elrasheid A H Kheirelseid; Nicola Miller; Kah Hoong Chang; Mary Nugent; Michael J Kerin
Journal:  J Gastrointest Oncol       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.